Trial Profile
Phase III trial of AD 04 (ultra-low dose ondansetron) for alcohol use disorder (second phase III trial).
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 18 Feb 2019
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary)
- Indications Alcoholism
- Focus Registrational; Therapeutic Use
- Sponsors ADial Pharmaceuticals
- 12 Feb 2019 According to an ADial Pharmaceuticals media release, the company expects to commence the trial in the first half of 2019.
- 01 Apr 2014 New trial record